April 10, 2023 - USA

Adis R&D Insight

SLA – Pipeline Town Hall

Ben Weintraub and

Jeff Southwood

WHY ADIS R&D INSIGHT

April 10, 2023 - USA 2

Why? – Experience, Expertise, and Timeliness

Editorial Staff—150+ highly qualified (PhD, MD, PharmD) staff in-house—Average writing experience = 7-10 years (some up to 20 years)—Expertise across extensive range of therapeutic areas—Rigorous training program—Global focus

inThought Team—10 years experience covering pharma for Wall Street—Practicing physicians on staff to provide the clinician’s perspective—Network of medical experts

Daily updates from company contacts, press releases, international conferences, company websites, and journals

April 10, 2023 - USA 3

Comprehensive pipeline of preclinical, clinical, and launched compounds, updated daily using sources

from around the world.

Why? – Scientific/Clinical Emphasis

In-depth reviews of launched products and compounds in development worldwide covering all indications, countries, and phases

Concise summaries of pivotal clinical trials with links to full study profiles in Adis Clinical Trials Insight

Comprehensive drug development history provides timeline for key events and milestones throughout the development process

Detailed synopsis of pharmacokinetics, pharmacodynamics, and adverse events broken out by indication

Global phase of development table documents progress by country/region

April 10, 2023 - USA 4

Extensively referenced profiles provide a narrative of each drug’s developmental history.

Why? – inThought Commercial Assessments

inThought Approvability Index—Probability of FDA approval—Available for all drugs in active clinical development—Based on specific factors in each phase of clinical development and

benchmarked against historical parameters—Absolute probability of approval as well as comparison to similar

agents

Revenue Forecasts—Models assess both currently approved and developmental drugs—Top-down, based on the addressable patient population —Forecasts seven years in the future and three years in the past—Models incorporate Wolters Kluwer’s Healthcare Analytics prescription

data

April 10, 2023 - USA 5

Single-source estimates provide a consistent view of FDA approvability and worldwide revenue potential.

Why? – Ease of Use

Intuitive search by name, class, mechanism, organization, development role, indication, patient segment, phase, and country

Refine search results to include drugs that are only available for licensing, small molecules, fixed combinations, orphan drugs, fast track status, biological, in active development

Save searches, send searches, revise searches

Alerts based on saved searches

April 10, 2023 - USA 6

Gilead Products by Phase17

Launched10 Phase II

28 Discontinued - Preclinical

12 No Develop-

ment Reported

Why? – Workflow Solution Tools

Create Excel and PowerPoint tables and graphs from search results

Export to Excel or HTML

Exported charts have links to the database that do not require a password – email to anyone

April 10, 2023 - USA 7

Adis R&D Insight: Gilead Pipeline

Indication Phase Country

BSF 208075 Pulmonary hypertension Marketed European Union, Japan, United Kingdom, USA

GSK1325760A Pulmonary hypertension Phase III Canada, South America

Letairis Idiopathic pulmonary fibrosis

Discontinued(III) Australia, European Union, Israel, New Zealand, North America,

Volibris®

Forvade® Cytomegalovirus infections

Marketed Australia, Brazil, Canada, European Union, New Zealand, Switzerland, USA

GS 504 Polyomavirus infections Discontinued(III) USA

HPMPC Herpes simplex virus infections

Discontinued(II) Canada, USA

Vistide® Human papillomavirus infections

Discontinued(II) European Union, USA

Kaposi's sarcoma Discontinued(II) USA

Viral infections Discontinued(II) USA

Human papillomavirus infections

Discontinued(Clinical) Belgium

Molluscum contagiosum Discontinued(Clinical) USA

Cancer Discontinued(Preclinical) USA

Rheumatic disorders Discontinued(Preclinical) Czech Republic

Daunorubicin citrate liposome injection

Kaposi's sarcoma Marketed Australia, Denmark, Finland, Spain, Sweden,

DaunoXome® Acute myeloid leukaemia Discontinued(II) USA

VS 103 Brain cancer Discontinued(II) USA

Breast cancer Discontinued(II) USA

Colorectal cancer Discontinued(II) USA

Lymphoma Discontinued(II) United Kingdom

Multiple myeloma Discontinued(II) USA

Non-Hodgkin's lymphoma Discontinued(II) USA

Ovarian cancer Discontinued(II) USA

Prostate cancer Discontinued(II) USA

Acute lymphoblastic leukaemia

Discontinued(I) France

Chronic lymphocytic leukaemia

Discontinued(I) USA

6 Daunorubicin liposomal

5 Cidofovir

2 Ambrisentan

Drug SynonymsDrug Development Phase

Why? – Customer Support

Ask-The-Expert service provides complimentary access to our team of scientific experts, financial analysts, and physician consultants to help answer your specific questions

April 10, 2023 - USA 8

EMERGING TRENDS

April 10, 2023 - USA 9

Emerging Trends

Pharma is increasing the pace and sophistication of licensing and acquisitions, driving a need for better information to screen candidates and more diverse and detailed information about each product

Emerging markets: visibility into India, China, and other emerging markets are becoming critical

Pharma doesn’t want a data dump…they need a strategic partner who can synthesize, condense, and summarize all the available information in a meaningful way that provides insights that are commercially relevant to their specific business and business issues

Mix of secondary and primary information, mix of facts and opinions

April 10, 2023 - USA 10

Drug database users want a single source for clinical data summaries, forecasts, commercial information, and business

development solutions.

FUTURE DEVELOPMENTS

April 10, 2023 - USA 11

Future Development

Single site source for clinical, commercial, deals, and regulatory

Incorporate other content from within Wolters Kluwer—Sales and managed care content from Source Healthcare Analytics—Clinical Trial content from Adis Clinical Trials Insight—Epidemiology and clinical content from UpToDate— inThought Research alert content

Partner with 3rd parties for additional commercial content—Consensus revenue estimates—Consensus launch dates—Patent expiry

April 10, 2023 - USA 12

Building a single source for clinical data summaries, forecasts, commercial information, and business

development solutions.